COLLIGO-HCM: A Multinational Observational Study of the Real-World Effectiveness of Mavacamten Among Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

Part of paid clinical trials in Durham, North Carolina.

Sponsor
Bristol-Myers Squibb
Study ID
NCT06372457
Status
Active Not Recruiting

Conditions

  • Hypertrophic Cardiomyopathy (HCM)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Approved Hypertrophic Cardiomyopathy drug treatments — DRUG
    As per product label
  • Mavacamten — DRUG
    As per product label

Study Details

COLLIGO-HCM is a global observational study that will conduct observational research of hypertrophic cardiomyopathy (HCM) treatment in real-world clinical practice.

Key Dates

First listed
Apr 18, 2024
Start date
Dec 1, 2023
Status verified
Apr 2026
Primary completion
Sep 29, 2025
Completion
Jun 30, 2026

Study Design

Enrollment
331 participants (actual)

Arms

  • Arm: Participants with Hypertrophic Cardiomyopathy (HCM)
    Participants with an available HCM diagnosis date and without evidence of an HCM phenocopy
  • Arm: Participants treated with mavacamten.

Primary Outcome Measure

Participant age at Hypertrophic Cardiomyopathy (HCM) diagnosis [ Time Frame: Baseline, index date ]

Locations (1)

FacilityCityStateZIPSite coordinators
IQVIADurhamNorth Carolina27703-

Find similar trials in Durham, NC

By research site
IQVIA· Durham, NC

Related Studies